Is Anika Therapeutics Inc (ANIK) overvalued? · rev $62.2M
Anika Therapeutics Inc (ANIK) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Anika Therapeutics Inc (ANIK) looks expensive on cached numbers — not a short thesis.
Latest reported ANIK revenue for 2026-06-30 was $62.2M. Net income was -$1.7M. ANIK currently screens at market cap $161.3M.
ANIK currently screens at market cap $161.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ANIK 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ANIK stock page for the full model, not this heading.
Not investment advice.